Insider Transactions in Q1 2026 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2026
|
Wendell Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
98
+0.3%
|
$6,174
$63.44 P/Share
|
|
Jan 15
2026
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
98
+0.32%
|
$6,174
$63.44 P/Share
|
|
Jan 15
2026
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
197
+1.04%
|
$12,411
$63.44 P/Share
|
|
Jan 15
2026
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+0.44%
|
$21,042
$63.44 P/Share
|
|
Jan 15
2026
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
197
+1.9%
|
$12,411
$63.44 P/Share
|
|
Jan 05
2026
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-22.92%
|
$900,000
$60.28 P/Share
|
|
Jan 05
2026
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+18.65%
|
$345,000
$23.26 P/Share
|
|
Jan 02
2026
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,798
-1.75%
|
$111,476
$62.63 P/Share
|
|
Jan 02
2026
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
885
+1.7%
|
$32,745
$37.63 P/Share
|